Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 19, Issue 4

July-August 2022

In this Issue

Clinical Trials Corner
Diffusion
Feature
Headlines from Washington
In Memoriam
Letter to the Editor
Mini Review
Off the Shelf
President's Column

Clinical Trials Corner

FEDORA: The Beginning of a Beautiful Friendship?

Bethan Psaila, MD, PhD,Mary Frances McMullin, MD, FRCP, FRCPath

View Articletitled, FEDORA: The Beginning of a Beautiful Friendship?

Diffusion

Minimal Residual Disease Negativity in Multiple Myeloma: One Good Season Is Not Enough

Gunjan Shah, MD, MS,Saad Usmani, MD, MBA, FACP

View Articletitled, Minimal Residual Disease Negativity in Multiple Myeloma: One Good Season Is Not Enough

Targeting AML in Unfit Patients: Ivosidenib/Azacitidine for IDH1-mutated AML

Alexander G. Hayden, MD,Christine M. McMahon, MD

View Articletitled, Targeting AML in Unfit Patients: Ivosidenib/Azacitidine for <em>IDH1</em>-mutated AML

From Unknown Unknowns to Known Unknowns: Intestinal Microbiota As a Previously Unappreciated Contributor to Cytokine Networks

Kate A. Markey, MBBS, PhD, FRACP, MClinRes

View Articletitled, From Unknown Unknowns to Known Unknowns: Intestinal Microbiota As a Previously Unappreciated Contributor to Cytokine Networks

What Contributes to Burnout Among Hematologists, and What Can We Do About It?

Eric Tseng, MD, MScCH, FRCPC

View Articletitled, What Contributes to Burnout Among Hematologists, and What Can We Do About It?

Putting the Novel Back in Oral Anticoagulants: Phase II Results of the Factor XIa Inhibitor Asundexian

Damon Houghton, MD

View Articletitled, Putting the Novel Back in Oral Anticoagulants: Phase II Results of the Factor XIa Inhibitor Asundexian

Rituximab in B-ALL: How Much and for Whom?

Kristen M. O'Dwyer, MD

View Articletitled, Rituximab in B-ALL: How Much and for Whom?

Targeting CD22 in Children With Relapsed B-ALL: At Least One Good Thing Happened in 2022

Holly Pariury, DO,Sarah K. Tasian, MD

View Articletitled, Targeting CD22 in Children With Relapsed B-ALL: At Least One Good Thing Happened in 2022

Trust Your Gut: Changes in Intestinal Microbiome Are Associated With Outcomes Following CAR-T Therapy

Loretta J. Nastoupil, MD

View Articletitled, Trust Your Gut: Changes in Intestinal Microbiome Are Associated With Outcomes Following CAR-T Therapy

ALK-positive Histiocytosis: An Old Target Shows Up in a New Disguise

Robert P. Hasserjian, MD

View Articletitled, ALK-positive Histiocytosis: An Old Target Shows Up in a New Disguise

Feature

Lymphohematopoietic Clones: Are They of Unknown Significance, Indeterminate Potential, or Indeterminate Progression?

Marshall A. Lichtman, MD

View Articletitled, Lymphohematopoietic Clones: Are They of Unknown Significance, Indeterminate Potential, or Indeterminate Progression?

Heparin-Induced Thrombocytopenia in COVID-19

Surbhi Shah, MBBS, MD,Alma Habib, MD

View Articletitled, Heparin-Induced Thrombocytopenia in COVID-19

War-Torn Care

Laura C. Michaelis, MD

View Articletitled, War-Torn Care

Headlines from Washington

The ASH Advocacy Leadership Institute Returns With First In-person Advocacy Event in Two Years

ASH Staff

View Articletitled, The ASH Advocacy Leadership Institute Returns With First In-person Advocacy Event in Two Years

In Memoriam

In Remembrance: Dr. Kwaku Ohene-Frempong

Maureen Achebe, MD, MPH,Isaac Odame, MB ChB, MRCP, FRCPath, FRCPCH, FRCPC,Alexis Thompson, MD, MPH

View Articletitled, In Remembrance: Dr. Kwaku Ohene-Frempong

Letter to the Editor

In Response to Back to HiDAC

Yaddanapudi Ravindranath, MBBS,Kristen M. O'Dwyer, MD

View Articletitled, In Response to Back to HiDAC

Mini Review

Treatment and Prevention of Venous Thromboembolism in Children: Current State and Future Directions

Marisol Betensky, MD, MPH,John M. Morrison, MD, PhD,Anthony A. Sochet, MD, MSc,Neil A. Goldenberg, MD, PhD

View Articletitled, Treatment and Prevention of Venous Thromboembolism in Children: Current State and Future Directions

Off the Shelf

Sickle Cell: Jamaica and Beyond: A Life, by Graham Serjeant

Claire Hilton, MD, PhD, FRCPsych

View Articletitled, <em>Sickle Cell: Jamaica and Beyond: A Life</em>, by Graham Serjeant

President's Column

Benign, Non-malignant, or Classical?

Jane N. Winter, MD

View Articletitled, Benign, Non-malignant, or Classical?

Cover Image

Cover Image

All Issues

Advertisement intended for health care professionals

Email alerts

Latest Issue Alert

Continuous Publishing Alert

New Journal Content Alert

Latest
Most Read

Vitamin A to Keep GVHD Away: Single Oral High-Dose Vitamin A Before Bone Marrow Transplant Reduces Graft-Versus-Host Disease in Pediatric and Young Adult Patients

Trainee Corner
A Career in Academia: Should I Stay or Should I Go?

Then and Now
Treatment for Acute Leukemia in Older Adults: Two Decades of Remarkable Progress

Does Sustained Monocytosis Always Mean CMML? A Case of Ras-Associated Autoimmune Leukoproliferative Disorder

ASH and Federal Officials Hold Town Hall on Sickle Cell Disease

Advertisement intended for health care professionals

Table of Contents

Clinical Trials Corner

FEDORA: The Beginning of a Beautiful Friendship?

Diffusion

Minimal Residual Disease Negativity in Multiple Myeloma: One Good Season Is Not Enough

Targeting AML in Unfit Patients: Ivosidenib/Azacitidine for IDH1-mutated AML

From Unknown Unknowns to Known Unknowns: Intestinal Microbiota As a Previously Unappreciated Contributor to Cytokine Networks

What Contributes to Burnout Among Hematologists, and What Can We Do About It?

Putting the Novel Back in Oral Anticoagulants: Phase II Results of the Factor XIa Inhibitor Asundexian

Rituximab in B-ALL: How Much and for Whom?

Targeting CD22 in Children With Relapsed B-ALL: At Least One Good Thing Happened in 2022

Trust Your Gut: Changes in Intestinal Microbiome Are Associated With Outcomes Following CAR-T Therapy

ALK-positive Histiocytosis: An Old Target Shows Up in a New Disguise

Feature

Lymphohematopoietic Clones: Are They of Unknown Significance, Indeterminate Potential, or Indeterminate Progression?

Heparin-Induced Thrombocytopenia in COVID-19

War-Torn Care

Headlines from Washington

The ASH Advocacy Leadership Institute Returns With First In-person Advocacy Event in Two Years

In Memoriam

In Remembrance: Dr. Kwaku Ohene-Frempong

Letter to the Editor

In Response to Back to HiDAC

Mini Review

Treatment and Prevention of Venous Thromboembolism in Children: Current State and Future Directions

Off the Shelf

Sickle Cell: Jamaica and Beyond: A Life, by Graham Serjeant

President's Column

Benign, Non-malignant, or Classical?

Email alerts

ASH Publications

American Society of Hematology

Issue Archive

Table of Contents

Clinical Trials Corner

Diffusion

Feature

Headlines from Washington

In Memoriam

Letter to the Editor

Mini Review

Off the Shelf

President's Column

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only